Bo Kyung Koo1, Sae Kyung Joo2, Donghee Kim3, Jeong Mo Bae4, Jeong Hwan Park4, Jung Ho Kim4, Won Kim2. 1. Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea. 3. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. 4. Department of Pathology, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.
Abstract
BACKGROUND AND AIM: We investigated the effects of PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7-TMC4 rs641738 variants on metabolic phenotypes and their combined effects on the histological severity of non-alcoholic fatty liver disease (NAFLD). METHODS: We genotyped rs738409, rs58542926, and rs641738 in biopsy-proven NAFLD patients (n = 416) and healthy controls (n = 109). Homeostasis model assessment of insulin resistance and adipose tissue insulin resistance were calculated. RESULTS: The rs738409 and rs58542926 variants, but not rs641738, were associated not only with non-alcoholic steatohepatitis (NASH) (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.46-2.73 and OR, 1.91; 95% CI, 1.04-3.51) but also with significant fibrosis (≥ F2) (OR, 1.53; 95% CI, 1.11-2.11 and OR, 1.88; 95% CI, 1.02-3.46) in NAFLD, even after adjustment for metabolic risk factors. Of both variants, only rs738409 was associated with homeostasis model assessment of insulin resistance and adipose tissue insulin resistance even in healthy controls (P = 0.046 and 0.002, respectively) as well as in the entire study cohort (P = 0.016 and 0.048, respectively). PNPLA3 and TM6SF2 risk variants additively increased the risk of NASH and significant fibrosis (OR per risk allele, 2.03; 95% CI, 1.50-2.73 and 1.61; 95% CI, 1.19-2.17). Even in subjects with low insulin resistance, the risk of NASH or significant fibrosis increased as the number of risk alleles increased (P = 0.008 and 0.020, respectively). CONCLUSIONS: PNPLA3 and TM6SF2 determine the risk of NASH and significant fibrosis, even after adjustment for insulin resistance, and exert an additive effect on NASH and significant fibrosis.
BACKGROUND AND AIM: We investigated the effects of PNPLA3rs738409, TM6SF2rs58542926, and MBOAT7-TMC4rs641738 variants on metabolic phenotypes and their combined effects on the histological severity of non-alcoholic fatty liver disease (NAFLD). METHODS: We genotyped rs738409, rs58542926, and rs641738 in biopsy-proven NAFLD patients (n = 416) and healthy controls (n = 109). Homeostasis model assessment of insulin resistance and adipose tissue insulin resistance were calculated. RESULTS: The rs738409 and rs58542926 variants, but not rs641738, were associated not only with non-alcoholic steatohepatitis (NASH) (odds ratio [OR], 2.00; 95% confidence interval [CI], 1.46-2.73 and OR, 1.91; 95% CI, 1.04-3.51) but also with significant fibrosis (≥ F2) (OR, 1.53; 95% CI, 1.11-2.11 and OR, 1.88; 95% CI, 1.02-3.46) in NAFLD, even after adjustment for metabolic risk factors. Of both variants, only rs738409 was associated with homeostasis model assessment of insulin resistance and adipose tissue insulin resistance even in healthy controls (P = 0.046 and 0.002, respectively) as well as in the entire study cohort (P = 0.016 and 0.048, respectively). PNPLA3 and TM6SF2 risk variants additively increased the risk of NASH and significant fibrosis (OR per risk allele, 2.03; 95% CI, 1.50-2.73 and 1.61; 95% CI, 1.19-2.17). Even in subjects with low insulin resistance, the risk of NASH or significant fibrosis increased as the number of risk alleles increased (P = 0.008 and 0.020, respectively). CONCLUSIONS:PNPLA3 and TM6SF2 determine the risk of NASH and significant fibrosis, even after adjustment for insulin resistance, and exert an additive effect on NASH and significant fibrosis.
Authors: Seung Mi Lee; Soo Heon Kwak; Ja Nam Koo; Ig Hwan Oh; Jeong Eun Kwon; Byoung Jae Kim; Sun Min Kim; Sang Youn Kim; Gyoung Min Kim; Sae Kyung Joo; Bo Kyung Koo; Sue Shin; Chanthalakeo Vixay; Errol R Norwitz; Chan-Wook Park; Jong Kwan Jun; Won Kim; Joong Shin Park Journal: Diabetologia Date: 2018-11-23 Impact factor: 10.122
Authors: Donghee Kim; Won Kim; Sae Kyung Joo; Jimin Han; Jung Ho Kim; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed Journal: J Gastroenterol Date: 2019-09-18 Impact factor: 7.527
Authors: Farah D R Al-Baiaty; Aziana Ismail; Zarina Abdul Latiff; Khairul Najmi Muhammad Nawawi; Raja Affendi Raja Ali; Norfilza Mohd Mokhtar Journal: Front Pediatr Date: 2021-07-08 Impact factor: 3.418
Authors: Umberto Vespasiani-Gentilucci; Chiara Dell'Unto; Antonio De Vincentis; Andrea Baiocchini; Marco Delle Monache; Roberto Cecere; Adriano Maria Pellicelli; Valerio Giannelli; Simone Carotti; Giovanni Galati; Paolo Gallo; Francesco Valentini; Franca Del Nonno; Davide Rosati; Sergio Morini; Raffaele Antonelli-Incalzi; Antonio Picardi Journal: Can J Gastroenterol Hepatol Date: 2018-03-14
Authors: Silvia Sookoian; Diego Flichman; Martin E Garaycoechea; Carla Gazzi; Julio San Martino; Gustavo O Castaño; Carlos J Pirola Journal: Sci Rep Date: 2018-03-23 Impact factor: 4.379